The prognosis from a CPG2 cancer is good and your risk of dying of prostate cancer is low compared to your risk of dying of other causes. The risk that the cancer may spread (metastasis) is also usually low. Immediate curative treatment may be of some benefit to you but needs to be weighed against the risk of side effects and complications. The alternative is active surveillance and then treatment if there are signs of change in the cancer.
The National Institute for Health and Care Excellence currently recommends that men diagnosed with CPG2 cancer are offered a choice between active surveillance and treatment.
This, however, depends on how old you are, your general state of health and your other medical conditions.
Other factors may also need to be considered, such as the amount of cancer in the biopsies or if there are any unusual features from your investigations.
For more accurate and personalised information of the likely benefit from treatment you can visit this website.
Based on the NICE recommendations you are likely to be offered:
